ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour hetero...
ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
About this item
Full title
Author / Creator
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Precision Medicine Tumour Board recommendations The board recommended next-generation sequencing-based liquid biopsy and regorafenib as sixth-line therapy (from April, 2020). ctDNA sequencing (Guardant360, Guardant Health Redwood City, CA, USA) showed an emerging BRAF Val600Glu mutation with a variant allelic frequency (VAF) of 25·9% and no RAS mut...
Alternative Titles
Full title
ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2646723993
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2646723993
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(22)00142-5
